Lupin has launched its generic version of Tobi inhalation solution in the US, the company said. The FDA granted final approval of Lupin’s ANDA for its tobramycin inhalation inhalation solution in March 2017.
The 300 mg/5 ml inhalation solution is indicated for the treatment of P. aeruginosa lung infections in cystic fibrosis patients.
Read the Lupin press release.
